Background Oral anticoagulants are established drugs of choice for the prevention and treatment of thromboembolic events. However, monitoring their safety remains warranted. Objective The aim was to analyze spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic. Setting Retrospective observational pharmacovigilance study. Methods Adverse drug reaction reports were obtained from the State Institute for Drug Control between January 2005 and November 2017. Reports related to warfarin, dabigatran, apixaban, and rivaroxaban received from healthcare professionals and patients were analyzed. Main outcome measure Frequency and nature of adverse drug reactions reported to oral anticoagulants. Results In total, 297 reports containing 672 adverse drug reactions were received; 269 reports were sent by healthcare professionals (85% by physicians). In 65% of all reports, reactions were due to direct oral anticoagulants. A higher total number of adverse drug reactions was associated with direct oral anticoagulants than with warfarin [reporting odds ratio (ROR): 10.76; confidence interval (CI): 8.70-13.32; p < 0.001]. Along with the increasing utilization of direct oral anticoagulants, the reporting rate gradually declined over time, especially for rivaroxaban and apixaban. Fatal outcomes were reported in 7%, mostly for dabigatran. Hemorrhagic reactions were the most frequently reported adverse drug reactions (37% associated with dabigatran, 28% with apixaban, 24% with warfarin, and 23% with rivaroxaban), and compared to warfarin, they were significantly more often associated with direct oral anticoagulants (ROR: 14.36; CI: 9.57-21.54; p < 0.001). Conclusion The number of adverse drug reaction reports related to oral anticoagulants in the Czech Republic was relatively low, compared to other studies, but 96% of the cases were serious. Data from spontaneous adverse drug reactions reporting should be further analyzed in order to obtain additional information on the safety profile of oral anticoagulants.

Centre for Pharmaceutical Research Research Group Clinical Pharmacology and Clinical Pharmacy Vrije Universiteit Brussel Brussels Belgium

Department of Pharmacovigilance State Institute for Drug Control Prague Czech Republic

Department of Social and Clinical Pharmacy Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic

Zobrazit více v PubMed

McDonald CJ, Kalisch Ellett LM, Barratt JD, Caughey GE. A cross-country comparison of rivaroxaban spontaneous adverse event reports and concomitant medicine use with the potential to increase the risk of harm. Drug Saf. 2014;37:1029–35. DOI

Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, et al. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol. 2017;83:1532–43. DOI

Caldeira D, Rodrigues R, Abreu D, Anes AM, Rosa MM, Ferreira JJ. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. Expert Opin Drug Saf. 2018;17:339–45. DOI

Lippi G, Favaloro EJ. Laboratory monitoring of direct oral anticoagulants (DOACs)—the perfect storm? Ann Transl Med. 2017;5:6. DOI

World Health Organization. Quality Assurance and Safety of Medicines Team. Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action. World Health Organization; 2002. https://apps.who.int/iris/handle/10665/67378 . Accessed 11 Oct 2020.

Carrasco-Garrido P, Hernández-Barrera V, Esteban-Hernández J, Jiménez-Trujillo I, Álvaro-Meca A, López de Andrés A, et al. Adverse drug reactions to anticoagulants in Spain: analysis of the Spanish National Hospital Discharge Data (2010–2013). BMJ Open. 2017 Jan;7(1):e013224. DOI

Mirosevic Skvrce N, Macolic Sarinic V, Mucalo I, Krnic D, Bozina N, Tomic S. Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. Croat Med J. 2011;52:604–14. DOI

Kopecna E, Descikova V, Vlcek J, Mlada J. Adverse drug reaction reporting in the Czech Republic 2005–2009. Int J Clin Pharm. 2011;33:683–9. DOI

McDonald CJ, Kalisch Ellett LM, Barratt JD, Caughey GE. An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiol Drug Saf. 2015;24:399–405. DOI

Terayama Y. Evaluation of the efficacy and safety of direct oral anticoagulants in Japanese patients-analysis of pharmaceuticals and medical devices agency data. J Stroke Cerebrovasc Dis. 2017;26(6):1171–81. DOI

Li R, Curtain C, Bereznicki L, Zaidi STR. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018;40:878–89. DOI

Narum S, Solhaug V, Myhr K, Johansen PW, Brørs O, Kringen MK. Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system. Br J Clin Pharmacol. 2011;71:254–62. DOI

Boudal P, Sommet A, Bagheri H, Pathak A, Montastruc JL. Bleedings induced by oral anticoagulants: a study of adverse drug reactions reported to Midi-Pyrénées PharmacoVigilance Centre between 2003 and 2006. Therapie. 2010;65:567–9. DOI

Papastergiou J, Kheir N, Ladova K, Rydant S, De Rango F, Antoniou S, et al. Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey. Int J Clin Pharm. 2017;39:1282–90. DOI

Maly J, Dvorackova S, Zimcikova E, Kubena AA, Kolar J, Vlcek J, et al. Patterns in anticoagulant utilization in the Czech Republic during 2007–2017. J Thromb Thrombolysis. 2019;47:305–11. DOI

State Institute for Drug Control. Annual reports. http://www.sukl.eu/sukl/publication-activities . Accessed 9 Oct 2020.

Micromedex® Healthcare Series. Thomson Reuters (Healthcare) Inc.; Greenwood Village. http://www.micromedexsolutions.com/ . Accessed 9 Oct 2020.

UpToDate© 2020, Lexicomp® Drug Interactions, Wolters Kluwer. https://www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist . Accessed 9 Oct 2020.

European Medicines Agency © 1995–2019, Eliquis: EPAR—Product Information, Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis . Accessed 4 October 2020.

European Medicines Agency © 1995–2019, Xarelto: EPAR—Product Information, Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto . Accessed 4 Oct 2020.

European Medicines Agency © 1995–2019, Pradaxa: EPAR—Product Information, Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa#product-information-section . Accessed 4 Oct 2020.

State Institute for Drug Control, Medicinal product database, Summary of Product Characteristics, Warfarin Orion. http://www.sukl.eu/modules/medication/search.php?lang=2 . Accessed 4 Oct 2020.

Eek AK, Strøm BO, Bakkehøi G, Stenberg-Nilsen H. Anticoagulant-associated adverse drug reactions in 2013–15. Tidsskr Nor Laegeforen. 2018. https://doi.org/10.4045/tidsskr.17.0706 . PubMed DOI

Fornasier G, Taborelli M, Francescon S, Polesel J, Aliberti M, De Paoli P, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm. 2018;40(4):795–802. DOI

Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol Drug Saf. 2015;24:152–8. DOI

Kampichit S, Pratipanawatr T, Jarernsiripornkul N. Confidence and accuracy in identification of adverse drug reactions reported by outpatients. Int J Clin Pharm. 2018;40:1559–67. DOI

Raghav S, Reutens D. Neurological sequelae of intrauterine warfarin exposure. Review. J Clin Neurosci. 2007;14(2):99–103. DOI

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. DOI

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. DOI

Caughey GE, Kalisch Ellett LM, Barratt JD, Shakib S. Apixaban, concomitant medicines and spontaneous reports of haemorrhagic events. Ther Adv Drug Saf. 2017;8(5):157–64. DOI

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. DOI

Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F. Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications. Pol Arch Med Wewn. 2016;126:552–61. PubMed

Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36:317–28. DOI